FHIR IG analytics| Package | hl7.fhir.uv.ebm |
| Resource Type | Composition |
| Id | Composition-399873.json |
| FHIR Version | R6 |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
Generated Narrative: Composition 399873
version: 5; Last updated: 2025-12-11 20:35:21+0000; Language: en
Profile: OutcomeMeasureReport
url: https://fevir.net/resources/Composition/399873
identifier: FEvIR Object Identifier/399873, FEvIR Linking Identifier/NCT03421379-outcome-measure-report
status: Final
type: Outcome Measure Report
date: 2025-12-11 20:35:21+0000
author: [No author listed.]
title: Outcome Measures Report for NCT03421379
custodian: Computable Publishing LLC
| Type | Target[x] |
| Cite As | Outcome Measures Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399873. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399873. Computable resource at: https://fevir.net/resources/Composition/399873#json. |
FHIR
FHIRsmith{
"resourceType": "Composition",
"id": "399873",
"meta": {
"versionId": "5",
"lastUpdated": "2025-12-11T20:35:21.032Z",
"profile": [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-measure-report"
]
},
"language": "en",
"text": {
"status": "generated",
"div": "<!-- snip (see above) -->"
},
"url": "https://fevir.net/resources/Composition/399873",
"identifier": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "ACSN",
"display": "Accession ID"
}
],
"text": "FEvIR Object Identifier"
},
"system": "https://fevir.net/FOI",
"value": "399873",
"assigner": {
"display": "Computable Publishing LLC"
}
},
{
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-outcome-measure-report",
"assigner": {
"display": "Computable Publishing LLC"
}
}
],
"status": "final",
"type": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "OutcomeMeasureReport",
"display": "OutcomeMeasureReport"
}
],
"text": "Outcome Measure Report"
},
"date": "2025-12-11T20:35:21.032Z",
"author": [
{
"display": "[No author listed.]"
}
],
"title": "Outcome Measures Report for NCT03421379",
"custodian": {
"reference": "Organization/118079",
"type": "Organization",
"display": "Computable Publishing LLC"
},
"relatesTo": [
{
"type": "cite-as",
"targetMarkdown": "Outcome Measures Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399873. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399873. Computable resource at: https://fevir.net/resources/Composition/399873#json."
}
],
"section": [
{
"title": "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration",
"focus": {
"reference": "EvidenceVariable/267226",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-primaryOutcome-0",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration (NCT03421379)"
},
"section": [
{
"title": "Outcome Measure Population Description",
"code": {
"text": "OutcomeMeasurePopulationDescription"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participant who completed both treatment visits and had evaluable treatment success data.</div>"
}
},
{
"title": "Outcome Measure Reporting Status",
"code": {
"text": "OutcomeMeasureReportingStatus"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title": "Outcome Measure Time Frame",
"code": {
"text": "OutcomeMeasureTimeFrame"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose up to 30 minutes post each glucagon administration</div>"
}
},
{
"title": "Outcome Group List",
"code": {
"text": "OutcomeGroupList"
},
"section": [
{
"title": "Glucagon Nasal Powder",
"code": {
"text": "OG000"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"
},
"entry": [
{
"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
}
]
},
{
"title": "Glucagon Hydrochloride Solution",
"code": {
"text": "OG001"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"
},
"entry": [
{
"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
}
]
}
]
},
{
"title": "Outcome Class List",
"code": {
"text": "OutcomeClassList"
},
"section": [
{
"title": "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration (NCT03421379)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/267226",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-primaryOutcome-0",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration (NCT03421379)"
},
"entry": [
{
"reference": "Evidence/267232",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-primaryOutcomeMeasure-0--OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Nasal Powder in NCT03421379"
},
{
"reference": "Evidence/267233",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-primaryOutcomeMeasure-0--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379"
},
{
"reference": "Evidence/267244",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-primaryOutcomeMeasure-0-OutcomeAnalysis-0-BetweenGroupAnalysis-OG000-OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration Statistical Analysis for Glucagon Nasal Powder vs Glucagon Hydrochloride Solution in NCT03421379"
}
]
}
]
}
]
},
{
"title": "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration",
"focus": {
"reference": "EvidenceVariable/267227",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-secondaryOutcome-0",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
},
"section": [
{
"title": "Outcome Measure Population Description",
"code": {
"text": "OutcomeMeasurePopulationDescription"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized patients who receive at least 1 dose of the study drug and have evaluable PD data.</div>"
}
},
{
"title": "Outcome Measure Reporting Status",
"code": {
"text": "OutcomeMeasureReportingStatus"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title": "Outcome Measure Time Frame",
"code": {
"text": "OutcomeMeasureTimeFrame"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>"
}
},
{
"title": "Outcome Group List",
"code": {
"text": "OutcomeGroupList"
},
"section": [
{
"title": "Glucagon Nasal Powder",
"code": {
"text": "OG000"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"
},
"entry": [
{
"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
}
]
},
{
"title": "Glucagon Hydrochloride Solution",
"code": {
"text": "OG001"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"
},
"entry": [
{
"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
}
]
}
]
},
{
"title": "Outcome Class List",
"code": {
"text": "OutcomeClassList"
},
"section": [
{
"title": "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/267227",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-secondaryOutcome-0",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
},
"entry": [
{
"reference": "Evidence/267234",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-secondaryOutcomeMeasure-0--OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379"
},
{
"reference": "Evidence/267235",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-secondaryOutcomeMeasure-0--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379"
}
]
}
]
}
]
},
{
"title": "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration",
"focus": {
"reference": "EvidenceVariable/267228",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-secondaryOutcome-1",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
},
"section": [
{
"title": "Outcome Measure Population Description",
"code": {
"text": "OutcomeMeasurePopulationDescription"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug and had evaluable PD data.</div>"
}
},
{
"title": "Outcome Measure Reporting Status",
"code": {
"text": "OutcomeMeasureReportingStatus"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title": "Outcome Measure Time Frame",
"code": {
"text": "OutcomeMeasureTimeFrame"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>"
}
},
{
"title": "Outcome Group List",
"code": {
"text": "OutcomeGroupList"
},
"section": [
{
"title": "Glucagon Nasal Powder",
"code": {
"text": "OG000"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"
},
"entry": [
{
"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
}
]
},
{
"title": "Glucagon Hydrochloride Solution",
"code": {
"text": "OG001"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"
},
"entry": [
{
"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
}
]
}
]
},
{
"title": "Outcome Class List",
"code": {
"text": "OutcomeClassList"
},
"section": [
{
"title": "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/267228",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-secondaryOutcome-1",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
},
"entry": [
{
"reference": "Evidence/267236",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-secondaryOutcomeMeasure-1--OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379"
},
{
"reference": "Evidence/267237",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-secondaryOutcomeMeasure-1--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379"
}
]
}
]
}
]
},
{
"title": "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration",
"focus": {
"reference": "EvidenceVariable/267229",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-secondaryOutcome-2",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
},
"section": [
{
"title": "Outcome Measure Population Description",
"code": {
"text": "OutcomeMeasurePopulationDescription"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug and had evaluable PK data.</div>"
}
},
{
"title": "Outcome Measure Reporting Status",
"code": {
"text": "OutcomeMeasureReportingStatus"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title": "Outcome Measure Time Frame",
"code": {
"text": "OutcomeMeasureTimeFrame"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>"
}
},
{
"title": "Outcome Group List",
"code": {
"text": "OutcomeGroupList"
},
"section": [
{
"title": "Glucagon Nasal Powder",
"code": {
"text": "OG000"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"
},
"entry": [
{
"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
}
]
},
{
"title": "Glucagon Hydrochloride Solution",
"code": {
"text": "OG001"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"
},
"entry": [
{
"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
}
]
}
]
},
{
"title": "Outcome Class List",
"code": {
"text": "OutcomeClassList"
},
"section": [
{
"title": "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/267229",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-secondaryOutcome-2",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
},
"entry": [
{
"reference": "Evidence/267238",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-secondaryOutcomeMeasure-2--OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379"
},
{
"reference": "Evidence/267239",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-secondaryOutcomeMeasure-2--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379"
}
]
}
]
}
]
},
{
"title": "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration",
"focus": {
"reference": "EvidenceVariable/267230",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-secondaryOutcome-3",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
},
"section": [
{
"title": "Outcome Measure Population Description",
"code": {
"text": "OutcomeMeasurePopulationDescription"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug and had evaluable PK data.</div>"
}
},
{
"title": "Outcome Measure Reporting Status",
"code": {
"text": "OutcomeMeasureReportingStatus"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title": "Outcome Measure Time Frame",
"code": {
"text": "OutcomeMeasureTimeFrame"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>"
}
},
{
"title": "Outcome Group List",
"code": {
"text": "OutcomeGroupList"
},
"section": [
{
"title": "Glucagon Nasal Powder",
"code": {
"text": "OG000"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"
},
"entry": [
{
"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
}
]
},
{
"title": "Glucagon Hydrochloride Solution",
"code": {
"text": "OG001"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"
},
"entry": [
{
"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
}
]
}
]
},
{
"title": "Outcome Class List",
"code": {
"text": "OutcomeClassList"
},
"section": [
{
"title": "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/267230",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-secondaryOutcome-3",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
},
"entry": [
{
"reference": "Evidence/267240",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-secondaryOutcomeMeasure-3--OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379"
},
{
"reference": "Evidence/267241",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-secondaryOutcomeMeasure-3--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379"
}
]
}
]
}
]
},
{
"title": "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration",
"focus": {
"reference": "EvidenceVariable/267231",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-secondaryOutcome-4",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
},
"section": [
{
"title": "Outcome Measure Population Description",
"code": {
"text": "OutcomeMeasurePopulationDescription"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug and had evaluable PK data.</div>"
}
},
{
"title": "Outcome Measure Reporting Status",
"code": {
"text": "OutcomeMeasureReportingStatus"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
}
},
{
"title": "Outcome Measure Time Frame",
"code": {
"text": "OutcomeMeasureTimeFrame"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>"
}
},
{
"title": "Outcome Group List",
"code": {
"text": "OutcomeGroupList"
},
"section": [
{
"title": "Glucagon Nasal Powder",
"code": {
"text": "OG000"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"
},
"entry": [
{
"display": "A single dose of 3 mg glucagon nasal powder was administered intranasally"
}
]
},
{
"title": "Glucagon Hydrochloride Solution",
"code": {
"text": "OG001"
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"
},
"entry": [
{
"display": "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
}
]
}
]
},
{
"title": "Outcome Class List",
"code": {
"text": "OutcomeClassList"
},
"section": [
{
"title": "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)",
"code": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "results",
"display": "Results"
}
]
},
"focus": {
"reference": "EvidenceVariable/267231",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-secondaryOutcome-4",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
},
"entry": [
{
"reference": "Evidence/267242",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-secondaryOutcomeMeasure-4--OG000",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379"
},
{
"reference": "Evidence/267243",
"type": "Evidence",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "NCT03421379-secondaryOutcomeMeasure-4--OG001",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379"
}
]
}
]
}
]
}
]
}